Chugai Pharmaceutical Co. Ltd.

In News

Chugai Pharmaceutical Co Ltd (4519) - MSN

MSN - Jul 14, 2026

ETFs Investing in Chugai Pharmaceutical Co., Ltd. Stocks - TradingView

TradingView - Jul 13, 2026

Jan 29,2026 | Chugai Relocates Head Office | News | CHUGAI PHARMACEUTICAL CO., LTD. - chugai-pharm.co.jp

chugai-pharm.co.jp - Jan 29, 2026

AWS Collaborates with Chugai Pharmaceutical Co. on Quantum-Inspired and Constraint Programming Methods for Cyclic Peptide-Protein Docking - Amazon Web Services (AWS)

Amazon Web Services (AWS) - Oct 13, 2025

Chugai Pharmaceutical Co Ltd (4519) - MSN

MSN - Jul 12, 2026

Chugai Pharmaceutical Co., Ltd. 2026 Q1 - Results - Earnings Call Presentation (OTCMKTS:CHGCY) 2026-04-24 - Seeking Alpha

Seeking Alpha - Apr 24, 2026

Chugai Pharma Manufacturing's FJ3 Project, designed and constructed by JGC JAPAN CORPORATION, awarded "Honorable Mention" in the 2026 FOYA by the International Society for Pharmaceutical Engineering (ISPE) | News Releases 2026 | JGC HOLDI - jgc.com

jgc.com - Apr 27, 2026

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing - Yahoo Finance

Yahoo Finance - Oct 17, 2025

Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma - Reuters

Reuters - Oct 17, 2025

Chugai to enhance kidney disease portfolio with Renalys - Pharmaceutical Technology

Pharmaceutical Technology - Oct 27, 2025

Chugai Pharmaceutical Co., Ltd. (TSE:4519) stock most popular amongst public companies who own 61%, while individual investors hold 20% - simplywall.st

simplywall.st - Dec 23, 2025

Latham & Watkins Advises Chugai Pharmaceutical in US$1.085 Billion License Agreement With Rani Therapeutics - Latham & Watkins LLP

Latham & Watkins LLP - Oct 22, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment